Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phacetoperane
- Development stage
- Preclinical
- Lead developer
- NLS Pharmaceutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Phacetoperane is a psychostimulant small molecule originally developed by Rhône-Poulenc in the 1950s. It is structurally a reverse ester of methylphenidate. The (R,R) enantiomer, known as levophacetoperane (also referred to as NLS-3), has been investigated for its therapeutic potential. Historically, phacetoperane was marketed as Lidepran® in Canada and Europe from 1959 to 1967 for the treatment of obesity and depression. It has also been used as an anorectic and a wakefulness-promoting agent for narcolepsy. More recently, NLS Pharmaceutics has been developing NLS-3 (levophacetoperane) as a potential treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) and narcolepsy, aiming to offer a safer and more potent alternative to existing stimulants.
- Brand names
- Lidépran
- Other names
- Levophacetoperane8228 R.P.phacetoperane free baseNLS-3NLS3NLS 3
02
Targets
NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on phacetoperane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phacetoperane.